BPC-157 and TB-500 are two synthetic peptides that appear together throughout the tissue-repair research literature. They are frequently mentioned in the same breath, which leads to a common assumption that they are interchangeable. They are not: they have different origins, different molecular structures, and distinct bodies of published research.
This article summarises how the two compounds are described in peer-reviewed laboratory and animal-model studies, for orientation within the research community. It does not describe human use, dosing, or therapeutic effects, and nothing here should be read as guidance for use in humans.
- BPC-157 is a 15-amino-acid peptide; TB-500 is a 17-amino-acid fragment of a larger protein. They are different molecules.
- Both are studied in tissue-repair and cell-migration research models, but along different mechanistic pathways.
- The evidence base for both is overwhelmingly preclinical — cell cultures and animal models — with no completed human efficacy trials and no head-to-head studies.
- Both are supplied for laboratory research use only and are not approved for human or veterinary use.
What is BPC-157?
BPC-157 is a synthetic, stable peptide made up of 15 amino acids (a pentadecapeptide). Its sequence corresponds to a fragment of a protein — “Body Protection Compound” — that has been identified in gastric juice. In the published literature it is most often studied in models of tissue repair and cytoprotection.
Mechanistic studies, carried out predominantly in rodent and in-vitro models, have examined its interaction with angiogenesis pathways — notably the upregulation of vascular endothelial growth factor (VEGF) and its receptor — and with the nitric oxide (NO) system. These are research observations in laboratory models and should not be read as therapeutic effects in humans.
What is TB-500?
TB-500 is a synthetic peptide corresponding to a 17-amino-acid active region of thymosin beta-4 (Tβ4), a naturally occurring protein of 43 amino acids. It is important to note that TB-500 is not the full thymosin beta-4 protein, but a fragment of it that is used in research.
In the published literature, TB-500 and thymosin beta-4 are studied largely for their role in actin regulation and cell migration. Research models have examined these pathways in wound-healing and cardiac-tissue contexts. As with BPC-157, these are mechanistic observations in laboratory and animal models, not demonstrated outcomes in humans.
BPC-157 and TB-500 side by side
| Property | BPC-157 | TB-500 |
|---|---|---|
| Class | Synthetic pentadecapeptide | Synthetic peptide fragment of thymosin β4 |
